title: [Heterozygous family hypercholesterolemia: study of use of statins under clinical practice conditions].
abstract: OBJECTIVE
  To compare the use profile of statins in patients with clinical diagnosis of heterozygous family hypercholesterolaemia (HFH) and the use profile of the general population treated with statins. DESIGN. Retrospective, observational study.
  
  
  METHODS
  Galician Health Service, Spain.
  
  
  METHODS
  Patients under 65 years old treated with statins.
  
  
  METHODS
  In patients with HFH: number of patients, age, gender, statins used and defined daily dose per patient and day (DDD/patient/day). Variables in the rest of the population treated with statins: number of patients, statins used and DDD/patient/day.
  
  
  RESULTS
  In a sample of 331 under-65 patients with HFH, 185 were men (55.86%) and 146 women (44.14%). Their average age was 44.56 years old (95% CI, 43.33-45.80), without statistically significant differences between men and women. Relevant differences in the daily mean consumption (DDD/patient/day) of statins between the studied sample and the rest of the under-65 population treated with statins were found (3.03 DDD/patient/day [95% CI, 2.70-3.36] vs 1.33 DDD/patient/day [95% CI, 1.16-1.40]; P< .001). These differences were caused by atorvastatin: 70% of HFH patients were being treated with atorvastatin (versus 37.6% of the rest of the population treated with statins). Differences in daily mean consumption of atorvastatin between HFH and the rest of the statin-treated population were also found (3.58 DDD/patient/day [95% CI, 3.15-4.02] vs 1.64 DDD/patient/day [95% CI, 1.37-1.90]; P< .001).
  
  
  CONCLUSIONS
  The DDD/patient/day of statins in HFH patients is double that of the rest of the population treated with statins. The different pattern of use of atorvastatin in HFH is the main reason for these results.
authors.affiliation: Dirección General de Farmacia y Productos Sanitarios, Consellería de Sanidade, 15702 Santiago de Compostela, A Coruña, Spain. manuel.portela.romero@sergas.es
authors.forename: Manuel
authors.initials: M
authors.lastname: Portela Romero
authors.forename: Julio
authors.initials: J
authors.lastname: Pombo Romero
authors.forename: Rosendo
authors.initials: R
authors.lastname: Bugarín González
authors.forename: Margarita
authors.initials: M
authors.lastname: Tasende Souto
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013030:Spain / Q000453:epidemiology; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors